Tag Archive: immunotherapy

Apr
17

The FDA has approved Merck’s Grastek tablet for grass pollen allergy, making it the second sublingual oral immunotherapy (SLIT)

The FDA has approved Merck’s Grastek tablet for grass pollen allergy, making it the second sublingual oral immunotherapy (SLIT) agent to gain that status following Greer’s Oralair. Grastek contains a single pollen extract of Timothy grass, which is cross-reactive with multiple other grass species. It is approved for adults up to age 65 and children …

Continue reading »

Jan
04

Oral immunotherapy for peanut allergy

In a pilot study, oral immunotherapy was found to protect some peanut–allergic patients even after therapy is discontinued. Twelve of 24 patients showed ongoing desensitization to peanuts four weeks after stopping immunotherapy, and none reported allergic reactions when contacted at a median of 40 months afterward. (Journal of Allergy and Clinical Immunology)